Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126685175 | 12668517 | 5 | F | 20160526 | 20160915 | 20160819 | 20160922 | EXP | RS-TAKEDA-2016MPI005459 | TAKEDA | 80.75 | YR | F | Y | 54.00000 | KG | 20160922 | MD | RS | RS |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126685175 | 12668517 | 1 | PS | VELCADE | BORTEZOMIB | 1 | Subcutaneous | 1.95 MG, QD | 21 | MG | Y | 437092 | 21602 | 1.95 | MG | INJECTION | QD | ||
| 126685175 | 12668517 | 2 | SS | VELCADE | BORTEZOMIB | 1 | Subcutaneous | 1.5 MG, QD | 21 | MG | Y | 437092 | 21602 | 1.5 | MG | INJECTION | QD | ||
| 126685175 | 12668517 | 3 | SS | PREDNISONE. | PREDNISONE | 1 | Oral | 90 MG, UNK | 30049099 | 0 | 90 | MG | |||||||
| 126685175 | 12668517 | 4 | SS | MELPHALAN | MELPHALAN | 1 | Oral | 6.75 MG/M2, UNK | 54 | MG | Y | 4370211 | 0 | 6.75 | MG/M**2 | ||||
| 126685175 | 12668517 | 5 | SS | MELPHALAN | MELPHALAN | 1 | Oral | 13.5 MG, QD | 54 | MG | Y | 4370211 | 0 | 13.5 | MG | QD | |||
| 126685175 | 12668517 | 6 | C | PRILENAP HL | 2 | Oral | 10 MG, BID | D | 0 | 10 | MG | TABLET | BID | ||||||
| 126685175 | 12668517 | 7 | C | TENSEC | 2 | Oral | 5 MG, UNK | D | 0 | 5 | MG | TABLET | |||||||
| 126685175 | 12668517 | 8 | C | TRIMETAZIDINE HYDROCHLORIDE | TRIMETAZIDINE DIHYDROCHLORIDE | 1 | Oral | 35 MG, BID | D | 0 | 35 | MG | TABLET | BID | |||||
| 126685175 | 12668517 | 9 | C | ACETYLSALICYLIC ACID | ASPIRIN | 1 | Oral | 100 MG, UNK | D | 0 | 100 | MG | TABLET | ||||||
| 126685175 | 12668517 | 10 | C | NOLPAZA | PANTOPRAZOLE SODIUM | 1 | Oral | 20 MG, BID | D | 0 | 20 | MG | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126685175 | 12668517 | 1 | Plasma cell myeloma |
| 126685175 | 12668517 | 3 | Plasma cell myeloma |
| 126685175 | 12668517 | 4 | Plasma cell myeloma |
| 126685175 | 12668517 | 6 | Hypertension |
| 126685175 | 12668517 | 7 | Hypertension |
| 126685175 | 12668517 | 8 | Hypertension |
| 126685175 | 12668517 | 9 | Hypertension |
| 126685175 | 12668517 | 10 | Prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126685175 | 12668517 | HO |
| 126685175 | 12668517 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126685175 | 12668517 | Anaemia | |
| 126685175 | 12668517 | Escherichia urinary tract infection | |
| 126685175 | 12668517 | Febrile neutropenia | |
| 126685175 | 12668517 | Neutropenia | |
| 126685175 | 12668517 | Parkinson's disease | |
| 126685175 | 12668517 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126685175 | 12668517 | 1 | 20160505 | 20160515 | 0 | |
| 126685175 | 12668517 | 2 | 20160526 | 0 | ||
| 126685175 | 12668517 | 3 | 20160505 | 20160508 | 0 | |
| 126685175 | 12668517 | 5 | 20160505 | 20160508 | 0 | |
| 126685175 | 12668517 | 6 | 20100407 | 0 | ||
| 126685175 | 12668517 | 7 | 20100407 | 0 | ||
| 126685175 | 12668517 | 8 | 20100407 | 0 | ||
| 126685175 | 12668517 | 9 | 20100407 | 0 | ||
| 126685175 | 12668517 | 10 | 20160505 | 0 |